A PTEN inhibitor displays preclinical activity against hepatocarcinoma cells

References

• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379:1245-55; PMID:22353262; http://dx.doi.org/10.1016/S0140-6736(11)61347-0
   PubMed Web of Science ®Google Scholar
• Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34; PMID:19095497; http://dx.doi.org/10.1016/S1470-2045(08)70285-7
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, De Oliveira AC, Santoro A, Raoul JL, Forner A, et al. SHARP Investigators Study Group, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx.doi.org/10.1056/NEJMoa0708857
   PubMed Web of Science ®Google Scholar
• Cervello M, McCubrey JA, Cusimano A, Lampiasi N, Azzolina A, Montalto G. Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 2012; 3:236-60; PMID:22470194; http://dx.doi.org/10.18632/oncotarget.466
   PubMed Web of Science ®Google Scholar
• Harding JJ, Abou-Alfa GK. Treating advanced hepatocellular carcinoma: How to get out of first gear. Cancer 2014; 120:3122-30; PMID:24898783; http://dx.doi.org/10.1002/cncr.28850
   PubMed Web of Science ®Google Scholar
• Llovet JM, Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin Cancer Res 2014; 20:2072-9; PMID:24589894; http://dx.doi.org/10.1158/1078-0432.CCR-13-0547
   PubMed Web of Science ®Google Scholar
• Costa JC, Gil J. Senescence: a new weapon for cancer therapy. Trends Cell Biol 2012; 22:211-9; PMID:22245068; http://dx.doi.org/10.1016/j.tcb.2011.11.006
   PubMed Web of Science ®Google Scholar
• Nardella C, Clohessy JG, Alimonti A, Pandolfi PP. Pro-senescence therapy for cancer treatment. Nat Rev Cancer 2011; 11:503-11; PMID:21701512; http://dx.doi.org/10.1038/nrc3057
   PubMed Web of Science ®Google Scholar
• Muehlich S, Gudermann T. Pro-senescence therapy for hepatocellular carcinoma. Aging 2013; 5:639-40; PMID:24057649
   PubMedGoogle Scholar
• Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011; 7:1149-67; PMID:21992728; http://dx.doi.org/10.2217/fon.11.95
   PubMed Web of Science ®Google Scholar
• Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Haupt Y, Hannan RD, Pearson RB. AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene 2012; 31:1949-62; PMID:21909130; http://dx.doi.org/10.1038/onc.2011.394
   PubMed Web of Science ®Google Scholar
• Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M, Koutcher JA, Scher HI, Ludwig T, Gerald W, Cordon-Cardo C, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005; 436:725-30; PMID:16079851; http://dx.doi.org/10.1038/nature03918
   PubMed Web of Science ®Google Scholar
• Nogueira V, Park Y, Chen CC, Xu PZ, Chen ML, Tonic I, Unterman T, Hay N. Akt determines replicative senescence and oxidative or oncogenic premature senescence and sensitizes cells to oxidative apoptosis. Cancer Cell 2008; 14:458-70; PMID:19061837; http://dx.doi.org/10.1016/j.ccr.2008.11.003
   PubMed Web of Science ®Google Scholar
• Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl CD, Kim SH, Klein-Szanto A, Diehl JA, Herlyn M, El-Deiry W, et al. AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene 2007; 26:2353-64; PMID:17043653; http://dx.doi.org/10.1038/sj.onc.1210025
   PubMed Web of Science ®Google Scholar
• Chen H, Shi B, Feng X, Kong W, Chen W, Geng L, Chen J, Liu R, Li X, Chen W, et al. Leptin and NAP2 promote mesenchymal stem cell senescence through activation of PI3K/Akt pathway in patients with systemic lupus erythematosus. Arthritis Rheumatol 2015; 67:2383-93; PMID:25989537; http://dx.doi.org/10.1002/art.39196
   PubMed Web of Science ®Google Scholar
• Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003; 97:1929-40; PMID:12673720; http://dx.doi.org/10.1002/cncr.11266
   PubMed Web of Science ®Google Scholar
• Yao YJ, Ping XL, Zhang H, Chen FF, Lee PK, Ahsan H, Chen CJ, Lee PH, Peacocke M, Santella RM, et al. PTEN/MMAC1 mutations in hepatocellular carcinomas. Oncogene 1999; 18:3181-5; PMID:10340391; http://dx.doi.org/10.1038/sj.onc.1202659
   PubMed Web of Science ®Google Scholar
• Bae JJ, Rho JW, Lee TJ, Yun SS, Kim HJ, Choi JH, Jeong D, Jang BC, Lee TY. Loss of heterozygosity on chromosome 10q23 and mutation of the phosphatase and tensin homolog deleted from chromosome 10 tumor suppressor gene in Korean hepatocellular carcinoma patients. Oncol Rep 2007; 18:1007-13; PMID:17786367
   PubMed Web of Science ®Google Scholar
• Fujiwara Y, Hoon DS, Yamada T, Umeshita K, Gotoh M, Sakon M, Nishisho I, Monden M. PTEN/MMAC1 mutation and frequent loss of heterozygosity identified in chromosome 10q in a subset of hepatocellular carcinomas. Jpn J Cancer Res 2000; 91:287-92; PMID:10760687; http://dx.doi.org/10.1111/j.1349-7006.2000.tb00943.x
   PubMedGoogle Scholar
• Rosivatz E, Matthews JG, McDonald NQ, Mulet X, Ho KK, Lossi N, Schmid AC, Mirabelli M, Pomeranz KM, Erneux C, et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol 2006; 1:780-90; PMID:17240976; http://dx.doi.org/10.1021/cb600352f
   PubMed Web of Science ®Google Scholar
• Alimonti A, Nardella C, Chen Z, Clohessy JG, Carracedo A, Trotman LC, Cheng K, Varmeh S, Kozma SC, Thomas G, et al. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. J Clin Invest 2010; 120:681-93; PMID:20197621; http://dx.doi.org/10.1172/JCI40535
   PubMed Web of Science ®Google Scholar
• Ewald JA, Desotelle JA, Wilding G, Jarrard D. Therapy-induced senescence in cancer. J Natl Cancer Inst 2010; 102:1536-46; PMID:20858887; http://dx.doi.org/10.1093/jnci/djq364
   PubMed Web of Science ®Google Scholar
• Gu J, Tamura JM, Yamada KM. Tumor suppressor PTEN inhibits integrin- and growth factor-mediated mitogen-activated protein (MAP) kinase signaling pathway. J Cell Biol 1998; 143:1375-83; PMID:9832564; http://dx.doi.org/10.1083/jcb.143.5.1375
   PubMed Web of Science ®Google Scholar
• Chetram MA, Hinton CV. PTEN regulation of ERK1/2 signaling in cancer. J Recept Signal Transduct Res 2012; 32:190-5; PMID:22737980; http://dx.doi.org/10.3109/10799893.2012.695798
   PubMed Web of Science ®Google Scholar
• Mak LH, Vilar R, Woscholski R. Characterisation of the PTEN inhibitor VO-OHpic. Chem Biol 2010; 3:157-63; http://dx.doi.org/10.1007/s12154-010-0041-7
   Google Scholar
• Silva SR, Zaytseva YY, Jackson LN, Lee EY, Weiss HL, Bowen KA, Townsend CM, Evers BM. The effect of PTEN on serotonin synthesis and secretion from the carcinoid cell line BON. Anticancer Res 2011; 31:1153-60; PMID:21508359
   PubMed Web of Science ®Google Scholar
• Wen PJ, Osborne SL, Zanin M, Low PC, Wang HT, Schoenwaelder SM, Jackson SP, Wedlich-Söldner R, Vanhaesebroeck B, Keating DJ, et al. Phosphatidylinositol(4,5)bisphosphate coordinates actin-mediated mobilization and translocation of secretory vesicles to the plasma membrane of chromaffin cells. Nat Commun 2012; 2:491; http://dx.doi.org/10.1038/ncomms1500
   Web of Science ®Google Scholar
• Zu L, Shen Z, Wesley J, Cai ZP. PTEN inhibitors cause a negative inotropic and chronotropic effect in mice. Eur J Pharmacol 2011; 650:298-302; PMID:20951693; http://dx.doi.org/10.1016/j.ejphar.2010.09.069
   PubMed Web of Science ®Google Scholar
• Zhu X, Shao ZH, Li C, Li J, Zhong Q, Learoyd J, Meliton A, Meliton L, Leff AR, Vanden Hoek TL. TAT-protein blockade during ischemia/reperfusion reveals critical role for p85 PI3K-PTEN interaction in cardiomyocyte injury. PLoS One 2014; 9:95622; http://dx.doi.org/10.1371/journal.pone.0095622
   Web of Science ®Google Scholar
• Spinelli L, Lindsay YE, Leslie NR. PTEN inhibitors: an evaluation of current compounds. Adv Biol Regul 2015; 57:102-11; PMID:25446882; http://dx.doi.org/10.1016/j.jbior.2014.09.012
   PubMedGoogle Scholar
• Courtois-Cox S, Genther Williams SM, Reczek EE, Johnson BW, McGillicuddy LT, Johannessen CM, Hollstein PE, MacCollin M, Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006; 6:459-72; http://dx.doi.org/10.1016/j.ccr.2006.10.003
   Web of Science ®Google Scholar
• Alimonti A, Carracedo A, Clohessy JG, Trotman LC, Nardella C, Egia A, Salmena L, Sampieri K, Haveman WJ, Brogi E, et al. Subtle variations in Pten dose determine cancer susceptibility. Nat Genet 2010; 42:454-8; PMID:20400965; http://dx.doi.org/10.1038/ng.556
   PubMed Web of Science ®Google Scholar
• Berger AH, Knudson AG, Pandolfi PP. A continuum model for tumour suppression. Nature 2011; 476:163-9; PMID:21833082; http://dx.doi.org/10.1038/nature10275
   PubMed Web of Science ®Google Scholar
• Rufini A, Tucci P, Celardo I, Melino G. Senescence and aging: the critical roles of p53. Oncogene 2013; 32:5129-43; PMID:23416979; http://dx.doi.org/10.1038/onc.2012.640
   PubMed Web of Science ®Google Scholar
• Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, et al. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 2010; 464:374-9; PMID:20237562; http://dx.doi.org/10.1038/nature08815
   PubMed Web of Science ®Google Scholar
• Moiseeva O, Lessard F, Acevedo-Aquino M, Vernier M, Tsantrizos YS, Ferbeyre G. Mutant lamin A links prophase to a p53 independent senescence program. Cell Cycle 2015; 14:2408-21; PMID:26029982; http://dx.doi.org/10.1080/15384101.2015.1053671
   PubMed Web of Science ®Google Scholar
• Liu L, Xie Y, Lou L. PI3K is required for insulin-stimulated but not EGF-stimulated ERK1/2 activation. Eur J Cell Biol 2006; 85:367-74; PMID:16406609; http://dx.doi.org/10.1016/j.ejcb.2005.11.005
   PubMed Web of Science ®Google Scholar
• Bouali S, Chrétien AS, Ramacci C, Rouyer M, Becuwe P, Merlin JL. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells. Oncol Rep 2009; 21:731-5; PMID:19212633
   PubMed Web of Science ®Google Scholar
• Steelman LS, Chappel WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implication for cancer and aging. Aging 2011; 3:192-222; PMID:21422497
   PubMedGoogle Scholar
• Cagnol S, Chambard JC. ERK and cell death: mechanism of ERK-induced cell death- apoptosis, autophagy and senescence. FEBS J 2009; 277:2-21; PMID:19843174; http://dx.doi.org/10.1111/j.1742-4658.2009.07366.x
   PubMed Web of Science ®Google Scholar
• Deschnes-Simard X, Kottakis F, Meloche S, Ferbeyre G. ERKs in cancer: friends or foes? Cancer Res 2014; 74:412-9; PMID:24408923; http://dx.doi.org/10.1158/0008-5472.CAN-13-2381
   PubMed Web of Science ®Google Scholar
• Lin AW, Barradas M, Stone JC, Van Aelst L, Serrano M, Lowe SW. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev 1998; 12:3008-19; PMID:9765203; http://dx.doi.org/10.1101/gad.12.19.3008
   PubMed Web of Science ®Google Scholar
• Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4; PMID:16079850; http://dx.doi.org/10.1038/nature03890
   PubMed Web of Science ®Google Scholar
• Cusimano A, Foderà D, D'Alessandro N, Lampiasi N, Azzolina A, Montalto G, Cervello M. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther 2007; 9:1461-8
   Google Scholar
• Simioni C, Martelli AM, Cani A, Cetin-Atalay R, McCubrey JA, Capitani S, Neri LM. The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget 2013; 4:1496-506; PMID:24036604; http://dx.doi.org/10.18632/oncotarget.1236
   PubMed Web of Science ®Google Scholar
• Wentz SC, Wu H, Yip-Schneider MT, Hennig M, Klein PJ, Sebolt-Leopold J, Schmidt CM. Targeting MEK is effective chemoprevention of hepatocellular carcinoma in TGF-α-transgenic mice. J Gastrointest Surg 2008; 12:30-7; PMID:17987349; http://dx.doi.org/10.1007/s11605-007-0396-4
   PubMed Web of Science ®Google Scholar
• Hennig M, Yip-Schneider MT, Wentz S, Wu H, Hekmatyar SK, Klein P, Bansal N, Schmidt CM. Targeting mitogen-activated protein kinase kinase with the inhibitor PD0325901, a derivative of CI-1040, decreases hepatocellular carcinoma growth in vitro and in mouse model systems. Hepatology 2010; 51:1218-25; PMID:20112426; http://dx.doi.org/10.1002/hep.23470
   PubMed Web of Science ®Google Scholar
• Cusimano A, Puleio R, D'Alessandro N, Loria GR, McCubrey JA, Montalto G, Cervello M. Cytotoxic activity of the novel small molecule AKT inhibitor SC66 in hepatocellular carcinoma cells. Oncotarget 2015; 6:1707-22; PMID:25596737; http://dx.doi.org/10.18632/oncotarget.2738
   PubMed Web of Science ®Google Scholar
• Bravatà V, Minafra L, Russo G, Forte GI, Cammarata FP, Ripamonti M, Casarino C, Augello G, Costantini F, Barbieri G, et al. High-dose Ionizing Radiation Regulates Gene Expression Changes in the MCF7 Breast Cancer Cell Line. Anticancer Res 2015; 35:2577-91
   PubMed Web of Science ®Google Scholar